Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin

Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet